Shanghai Kehua Bio-Engineering Co.,Ltd (SHE:002022)
China · Delayed Price · Currency is CNY 5.97
+0.04 (0.67%)
Apr 30, 2026, 3:04 PM CST
SHE:002022 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,627 | 1,746 | 2,417 | 6,916 | 4,844 |
Other Revenue | 15.14 | 13.21 | 11.47 | 54.29 | 10.62 |
| 1,642 | 1,759 | 2,428 | 6,970 | 4,854 | |
Revenue Growth (YoY) | -6.63% | -27.55% | -65.16% | 43.58% | 16.82% |
Cost of Revenue | 1,254 | 1,247 | 1,483 | 3,405 | 2,208 |
Gross Profit | 388.54 | 511.95 | 944.72 | 3,564 | 2,647 |
Selling, General & Admin | 731.35 | 769.85 | 877.11 | 1,258 | 809.79 |
Research & Development | 189.62 | 198.67 | 241.36 | 250.49 | 148.47 |
Other Operating Expenses | 1.45 | 4.34 | -41.22 | -118.05 | 6.08 |
Operating Expenses | 1,079 | 1,161 | 1,086 | 1,448 | 978.51 |
Operating Income | -690.04 | -648.69 | -140.95 | 2,117 | 1,668 |
Interest Expense | -23.32 | -42.23 | -43.74 | -40.06 | -40.15 |
Interest & Investment Income | 8.14 | 33.43 | 53.92 | 48.26 | 26.79 |
Currency Exchange Gain (Loss) | 2.84 | -0.58 | 3.4 | 78.75 | -28.61 |
Other Non Operating Income (Expenses) | -0.07 | -6.38 | -12.62 | -18.39 | -2.16 |
EBT Excluding Unusual Items | -702.45 | -664.44 | -140 | 2,185 | 1,624 |
Impairment of Goodwill | -66.21 | -25.51 | -41.82 | -109.6 | -9.79 |
Gain (Loss) on Sale of Investments | 0.03 | -1.17 | 1.47 | - | -1.96 |
Gain (Loss) on Sale of Assets | 3.87 | 4.21 | 5.02 | 4.53 | 2.06 |
Asset Writedown | -54.42 | -67.74 | -40.78 | -36.38 | -5.82 |
Other Unusual Items | 7.07 | 19.69 | 30.24 | 20.74 | 28.9 |
Pretax Income | -812.11 | -734.85 | -185.61 | 2,065 | 1,637 |
Income Tax Expense | 72.68 | -4.2 | -8.62 | 332.96 | 283.58 |
Earnings From Continuing Operations | -884.79 | -730.65 | -176.99 | 1,732 | 1,354 |
Minority Interest in Earnings | 152.65 | 90.05 | -57.03 | -760.66 | -503.41 |
Net Income | -732.14 | -640.6 | -234.01 | 971.56 | 850.41 |
Net Income to Common | -732.14 | -640.6 | -234.01 | 971.56 | 850.41 |
Net Income Growth | - | - | - | 14.25% | 25.92% |
Shares Outstanding (Basic) | 514 | 505 | 514 | 514 | 514 |
Shares Outstanding (Diluted) | 514 | 505 | 514 | 533 | 532 |
Shares Change (YoY) | 1.86% | -1.83% | -3.55% | 0.27% | 3.75% |
EPS (Basic) | -1.42 | -1.27 | -0.46 | 1.89 | 1.65 |
EPS (Diluted) | -1.42 | -1.27 | -0.46 | 1.82 | 1.60 |
EPS Growth | - | - | - | 13.94% | 21.37% |
Free Cash Flow | -116.86 | -304.94 | -805.82 | 1,726 | 863.19 |
Free Cash Flow Per Share | -0.23 | -0.60 | -1.57 | 3.24 | 1.62 |
Dividend Per Share | - | - | - | 0.600 | 0.065 |
Dividend Growth | - | - | - | 823.08% | -67.50% |
Gross Margin | 23.66% | 29.10% | 38.91% | 51.14% | 54.52% |
Operating Margin | -42.01% | -36.87% | -5.80% | 30.37% | 34.36% |
Profit Margin | -44.57% | -36.41% | -9.64% | 13.94% | 17.52% |
Free Cash Flow Margin | -7.12% | -17.33% | -33.19% | 24.76% | 17.78% |
EBITDA | -485.45 | -427.54 | 48.41 | 2,283 | 1,796 |
EBITDA Margin | -29.56% | -24.30% | 1.99% | 32.75% | 37.01% |
D&A For EBITDA | 204.59 | 221.14 | 189.36 | 165.77 | 128.27 |
EBIT | -690.04 | -648.69 | -140.95 | 2,117 | 1,668 |
EBIT Margin | -42.01% | -36.87% | -5.80% | 30.37% | 34.36% |
Effective Tax Rate | - | - | - | 16.12% | 17.32% |
Revenue as Reported | 1,642 | 1,759 | 2,428 | 6,970 | 4,854 |
Advertising Expenses | 6.85 | 16.47 | 30.12 | 59.59 | 47.01 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.